ARTICLE | Clinical News

Avastin bevacizumab: Phase III data

January 30, 2012 8:00 AM UTC

The open-label, international Phase III ML 18147 trial in patients with mCRC who progressed after first-line treatment with Avastin plus chemotherapy showed that IV Avastin plus an alternate chemotherapy regimen met the primary endpoint of OS vs. chemotherapy alone. OS was measured from the time at which patients were randomized to second-line treatment. Patients received an irinotecan- or oxaliplatin-based chemotherapy regimen in the first-line setting and were switched to the opposite regimen in the second-line setting. ...